Von Willebrand factor for menorrhagia: A survey and literature review

Haemophilia

Volumn 22, Issue 3, 2016, Pages 397-402

  Ragni, M V ^a,b   Machin, N ^a   Malec, L M ^b,c   James, A H ^d   Kessler, C M ^e   Konkle, B A ^f   Kouides, P A ^g   Neff, A T ^h   Philipp, C S ⁱ   Brambilla, D J ^j  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f BloodWorks Northwest   (United States)

^g ROCHESTER GENERAL HOSPITAL   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j RTI INTERNATIONAL   (United States)

more..

Author keywords

Menorrhagia; Von Willebrand disease; Von Willebrand factor; Women's health

Indexed keywords

AMINOCAPROIC ACID; DESMOPRESSIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; ANTIFIBRINOLYTIC AGENT; ARGIPRESSIN[1 DEAMINO];

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH SURVEY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STUDY DESIGN; VON WILLEBRAND DISEASE; WOMEN'S HEALTH; COMPLICATION; FACTUAL DATABASE; VON WILLEBRAND DISEASES;

ANTIFIBRINOLYTIC AGENTS; CONTRACEPTIVES, ORAL; DATABASES, FACTUAL; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MENORRHAGIA; TRANEXAMIC ACID; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84957712009     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12898     Document Type: Article

References (32)

1. Rodeghiero F, Castaman G, Dini E. Epidemiologic investigation of the prevalence of von Willebrand disease. Blood 1987; 69: 454-9.
2. Sadler JE, Budde U, Eikenboom JCJ. Update on the pathophysiology and classification of von Wilebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
3. Nichols WL, Hultin MB, James AH et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart Lung and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
4. Ragni MV, Bontempo FA, Cortese-Hassett AL. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313-7.
5. James A, Ragni MV, Picozzi V. ASH Special Educational Symposium: bleeding disorders in premenopausal women: another public health crisis for hematology. Hematology 2006; 2006: 474-85.
6. National Institute for Health and Clinical Excellence. NICE Clinical Guidelines 44: Heavy Menstrual Bleeding. London, UK: National Health Service, 2007.
7. Kadir RA, Edlund M, von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia 2010; 16: 832-9.
8. Hallberg L, Milsson L. Determinants of menstrual blood loss. Scand J Lab Invest 1996; 16: 244-8.
9. James AH. Women and bleeding disorders. Haemophilia 2010; 16(Suppl 5): 160-7.
10. ACOG. Management of Anovulatory Bleeding. Washington, DC: American College of Obstetricians and Gynecologists, 2000.
11. Kouides PA, Byams VR, Philipp CS et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 212-20.
12. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
13. Mannucci PM. Desmopressin in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21.
14. Schlesinger KW, Rinder HM, Ragni MV. Women with bleeding disorders. In: Ehrenthal DB, Hoffman MK, Hillard PJ eds. Menstrual Disorders. Women's Health Book Series. Philadelphia: American College of Physicians/American Society of Internal Medicine, 2006: 171-95.
15. Byams VR, Baker J, Brown DL et al. Baseline characteristics of females with bleeding disorders receiving care in the US. HTC Network. Natl Conf Blood Disorders Pub Health 2010; 3: 3 (abstract).
16. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-93.
17. Lethagen S. Desmopressin in the treatment of women's bleeding disorders. Haemophilia 1999; 5: 233-7.
18. Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia 2008; 14: 571-8.
19. Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey (ISTH). Thromb Haemost 1995; 74: 784-90.
20. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 1425-8.
21. ®) in women with von Willebrand disease and menorrhagia. Thromb Haemost 2011; 106: 641-5.
22. Turecek PL, Schrenk G, Rottensteiner H et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost 2010; 36: 510-21.
23. Mannucci PM, Kempton C, Miller C et al. Pharmokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a multicenter prospective clinical trial. Blood 2013; 122: 648-57.
24. Gill J, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek F, Obermann-Supetzky O. Safety, efficacy, and pharmacokinetics of a recombinant von Willebrand factor in patients with severe von Willebrand disease. Blood 2015; 126: 2038-46.
25. Medical Product Safety. In Healthy People 2020. Available at http://www.healthypeople.gov/2020/topics-objectives/blood-disorders-and-blood-safety. Accessed August 21, 2015
26. Cines DB, Blajchman MA, High KA, Bussell JB, for the State-of-the-Science Symposium Hemostasis-Thrombosis Committee. Clinical trial opportunities in hemostasis and thrombosis. Proceedings of the NHLBI State-of-the-Science Symposium. Am J Med 2012; 87: 237-8.
27. Abshire TC, Federici AB, Alvarez MT et al. Prophylaxis in severe forms of von Willebrand disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76-81.
28. ®): a single centre experience. Haemophilia 2014; 20: 846-53.
29. ®, a new generation von Willebrand factor/factor VIII. Haemophilia 2009; 15: 122-30.
30. Holm E, Abshire TC, Bowen J et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis network. Blood Coagul Fibrinolysis 2015; 26: 383-8.
31. ® P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res 2014; 135: 479-84.
32. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG 2000; 107: 320-2.